The U.S. FDA has approved a subcutaneous formulation of Merck's Keytruda, aiming to extend the market life of the world's top-selling cancer drug by easing administration. This new approval comes amid multiple positive regulatory outcomes, including CHMP recommendations for subcutaneous Lunsumio and a novel insulin combination therapy (icodec/semaglutide). These developments mark significant progress in expanding convenient therapeutic options for cancer and diabetes patients, positioning these treatments for broader clinical adoption.